KR20050075012A - 항암제에 의해 유발된 말초신경증의 예방 및/또는 치료를위한 아세틸-ｌ-카르니틴 - Google Patents

항암제에 의해 유발된 말초신경증의 예방 및/또는 치료를위한 아세틸-ｌ-카르니틴 Download PDF

Info

Publication number
KR20050075012A
KR20050075012A KR1020057008678A KR20057008678A KR20050075012A KR 20050075012 A KR20050075012 A KR 20050075012A KR 1020057008678 A KR1020057008678 A KR 1020057008678A KR 20057008678 A KR20057008678 A KR 20057008678A KR 20050075012 A KR20050075012 A KR 20050075012A
Authority
KR
South Korea
Prior art keywords
anticancer agent
carnitine
acid
acetyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057008678A
Other languages
English (en)
Korean (ko)
Inventor
클라우디오 카바차
클라우디오 피사노
로레다나 베스치
Original Assignee
씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이. filed Critical 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이.
Publication of KR20050075012A publication Critical patent/KR20050075012A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020057008678A 2002-11-13 2003-10-23 항암제에 의해 유발된 말초신경증의 예방 및/또는 치료를위한 아세틸-ｌ-카르니틴 Ceased KR20050075012A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/292,823 US20030199535A1 (en) 1998-07-30 2002-11-13 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
US10/292,823 2002-11-13

Publications (1)

Publication Number Publication Date
KR20050075012A true KR20050075012A (ko) 2005-07-19

Family

ID=32312146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057008678A Ceased KR20050075012A (ko) 2002-11-13 2003-10-23 항암제에 의해 유발된 말초신경증의 예방 및/또는 치료를위한 아세틸-ｌ-카르니틴

Country Status (19)

Country Link
US (2) US20030199535A1 (enExample)
EP (1) EP1562577B1 (enExample)
JP (1) JP2006508958A (enExample)
KR (1) KR20050075012A (enExample)
CN (1) CN1708297A (enExample)
AR (1) AR041947A1 (enExample)
AT (1) ATE526958T1 (enExample)
AU (2) AU2003283807B2 (enExample)
BR (1) BR0316131A (enExample)
CA (1) CA2505937C (enExample)
CY (1) CY1112399T1 (enExample)
DK (1) DK1562577T3 (enExample)
ES (1) ES2374503T3 (enExample)
MX (1) MXPA05004752A (enExample)
PL (1) PL379244A1 (enExample)
PT (1) PT1562577E (enExample)
SI (1) SI1562577T1 (enExample)
TW (1) TWI362260B (enExample)
WO (1) WO2004043454A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018767A2 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
WO2008136374A1 (ja) * 2007-04-26 2008-11-13 Nippon Shinyaku Co., Ltd. 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物
EP2191836B1 (en) * 2007-08-31 2012-05-23 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
MX2010004859A (es) * 2007-10-30 2010-06-21 Trophos Nueva composicion para tratar los efectos secundarios del tratamiento anticanceroso.
US20120208883A1 (en) * 2008-12-01 2012-08-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Treatment of oncological diseases
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
JP7075937B2 (ja) 2016-11-09 2022-05-26 キアゲン サイエンシーズ， エルエルシー Ｓｅｑｕｅｎｃｉｎｇ－Ｂｙ－Ｓｙｎｔｈｅｓｉｓ法におけるイメージング試薬としての光防護性混合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
US4599352A (en) * 1984-03-01 1986-07-08 The United States Of America As Represented By The Department Of Health And Human Services Antineoplastic platinum (IV) complexes and compositions
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
JP4703851B2 (ja) * 1998-07-30 2011-06-15 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Ｌ−カルニチンおよびそのアルカノイル誘導体の、抗癌作用を有する医薬品の製造のための使用

Also Published As

Publication number Publication date
WO2004043454A1 (en) 2004-05-27
MXPA05004752A (es) 2005-08-02
ES2374503T3 (es) 2012-02-17
CA2505937C (en) 2011-07-26
ATE526958T1 (de) 2011-10-15
SI1562577T1 (sl) 2012-01-31
US20030199535A1 (en) 2003-10-23
CA2505937A1 (en) 2004-05-27
PT1562577E (pt) 2012-01-12
AU2009201384A1 (en) 2009-05-07
DK1562577T3 (da) 2012-01-23
JP2006508958A (ja) 2006-03-16
AU2003283807A1 (en) 2004-06-03
AU2003283807B2 (en) 2009-12-03
AR041947A1 (es) 2005-06-01
CN1708297A (zh) 2005-12-14
EP1562577B1 (en) 2011-10-05
US20060183798A1 (en) 2006-08-17
EP1562577A1 (en) 2005-08-17
BR0316131A (pt) 2005-09-27
CY1112399T1 (el) 2015-12-09
TW200410683A (en) 2004-07-01
TWI362260B (en) 2012-04-21
PL379244A1 (pl) 2006-08-07

Similar Documents

Publication Publication Date Title
US20080194683A1 (en) Medicament for preventing and/or treating peripheral neuropathies
KR960008230B1 (ko) 중추신경계의 산화적 손상에 관련된 질병들을 억제하기 위한 조성물들
EP0912184B1 (en) Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
AU2009201384A1 (en) Acetyl-L-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
US20210077487A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
AU2009215329B2 (en) Combination comprising paclitaxel for treating ovarian cancer
WO2008118785A2 (en) Methods for treating depression using immediate-impact treatments and d-cycloserine
US20060167026A1 (en) Antipsychotic molecular-targeting epithelial growth factor receptor
CA2483857A1 (en) Use of dimesna for mitigating taxane induced neurotoxicity
KR20050085681A (ko) 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
US7649017B2 (en) Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same
EP0147185A2 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
WO2019082428A1 (ja) 認知症の予防及び／又は治療剤
US11446264B2 (en) Memory manipulation via modification of protein kinase C zeta activity
HK1084027A (en) Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
AU2005230924A1 (en) Combination therapies with epothilones and carboplatin
HK1018745B (en) Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
MXPA06010921A (en) Combination therapies with epothilones and carboplatin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050513

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20081021

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100826

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100826

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20110216

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20101129

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20111220

Appeal identifier: 2011101001152

Request date: 20110216

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110216

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110216

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20101013

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20081021

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20110407

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110216

Effective date: 20111220

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20111220

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20110216

Decision date: 20111220

Appeal identifier: 2011101001152